Literature DB >> 34064136

Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines.

Han Xu1, Jing Huang1, Zhaolu Liu1, Xin Li1, Kangfeng Wang1, Erling Feng1, Jun Wu1, Li Zhu1, Kaihu Yao2, Chao Pan1, Hengliang Wang1.   

Abstract

Pertussis is an acute respiratory tract infection caused by Bordetella pertussis. Even though its current vaccine coverage is relatively broad, they still have some shortcomings such as short protection time and might be incapable of blocking the spread of the disease. In this study, we developed new pertussis vaccine candidates by separately fusing three pertussis antigens (B. pertussis fimbriae 2 "Fim2", pertussis toxin S1 subunit "PtxS1", and filamentous hemagglutinin "FHA1877-2250") to each of two immune-boosting carrier proteins (B subunits of AB5 toxin family: cholera toxin B subunit "CTB" and shiga toxin B subunit "StxB"). We then immunized mice with these fusion antigens and found that they significantly increased the serum antibody titers and elicited high bactericidal activity against B. pertussis. After CTB-or StxB-fused antigen-immunized mice were challenged with a non-lethal dose of B. pertussis, the bacterial loads in different tissues of these mice were significantly reduced, and their lung damage was nearly invisible. Furthermore, we also demonstrated that these candidate vaccines could provide strong prophylactic effects against a lethal challenge with B. pertussis. Overall, our candidate vaccines conferred better immune protection to mice compared with pertussis antigen alone. This B5 subunit-based vaccine strategy provides a promising option for vaccine design.

Entities:  

Keywords:  Bordetella pertussis; filamentous hemagglutinin; fimbriae; fusion antigen; immunological evaluation; pertussis; pertussis toxin

Year:  2021        PMID: 34064136     DOI: 10.3390/vaccines9060542

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  31 in total

Review 1.  Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations.

Authors:  Emmanuel Vidor; Stanley A Plotkin
Journal:  Hum Vaccin       Date:  2008-09-02

Review 2.  Structure, biological functions and applications of the AB5 toxins.

Authors:  Travis Beddoe; Adrienne W Paton; Jérôme Le Nours; Jamie Rossjohn; James C Paton
Journal:  Trends Biochem Sci       Date:  2010-03-02       Impact factor: 13.807

Review 3.  CDC update on pertussis surveillance and Tdap vaccine recommendations.

Authors:  Thomas A Clark; Nichole Bobo
Journal:  NASN Sch Nurse       Date:  2012-11

Review 4.  Pertussis Across the Globe: Recent Epidemiologic Trends From 2000 to 2013.

Authors:  Tina Tan; Tine Dalby; Kevin Forsyth; Scott A Halperin; Ulrich Heininger; Daniela Hozbor; Stanley Plotkin; Rolando Ulloa-Gutierrez; Carl Heinz Wirsing von König
Journal:  Pediatr Infect Dis J       Date:  2015-09       Impact factor: 2.129

Review 5.  Pertussis vaccines and protective immunity.

Authors:  Parul Kapil; Tod J Merkel
Journal:  Curr Opin Immunol       Date:  2019-05-09       Impact factor: 7.486

Review 6.  Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.

Authors:  Susanna Esposito; Paola Stefanelli; Norman K Fry; Giorgio Fedele; Qiushui He; Pauline Paterson; Tina Tan; Markus Knuf; Carlos Rodrigo; Catherine Weil Olivier; Katie L Flanagan; Ivan Hung; Iria Lutsar; Kathryn Edwards; Miguel O'Ryan; Nicola Principi
Journal:  Front Immunol       Date:  2019-07-03       Impact factor: 7.561

7.  Development of Rift Valley fever (RVF) vaccine by genetic joining of the RVF-glycoprotein Gn with the strong adjuvant subunit B of cholera toxin (CTB) and expression in bacterial system.

Authors:  Essam H Ibrahim; Ramadan Taha; Hamed A Ghramh; Mona Kilany
Journal:  Saudi J Biol Sci       Date:  2018-08-22       Impact factor: 4.219

8.  Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.

Authors:  Yinghua Xu; Yaying Wang; Yajun Tan; Huajie Zhang; Lijie Wu; Lichan Wang; Qiming Hou; Shumin Zhang
Journal:  BMC Microbiol       Date:  2009-12-29       Impact factor: 3.605

9.  Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity.

Authors:  Salvador F Ausar; Shaolong Zhu; Jessica Duprez; Michael Cohen; Thomas Bertrand; Valérie Steier; Derek J Wilson; Stephen Li; Anthony Sheung; Roger H Brookes; Artur Pedyczak; Alexey Rak; D Andrew James
Journal:  Commun Biol       Date:  2020-08-05

10.  Safety and immunogenicity of a new glycoengineered vaccine against Acinetobacter baumannii in mice.

Authors:  Xin Li; Chao Pan; Zhicheng Liu; Peng Sun; Xiaoting Hua; Erling Feng; Yunsong Yu; Jun Wu; Li Zhu; Hengliang Wang
Journal:  Microb Biotechnol       Date:  2021-03-23       Impact factor: 5.813

View more
  4 in total

1.  Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection.

Authors:  Xin Li; Chao Pan; Peng Sun; Zhehui Peng; Erling Feng; Jun Wu; Hengliang Wang; Li Zhu
Journal:  Nano Res       Date:  2021-08-12       Impact factor: 8.897

2.  Construction of Orthogonal Modular Proteinaceous Nanovaccine Delivery Vectors Based on mSA-Biotin Binding.

Authors:  Yixin Shi; Chao Pan; Kangfeng Wang; Yan Liu; Yange Sun; Yan Guo; Peng Sun; Jun Wu; Ying Lu; Li Zhu; Hengliang Wang
Journal:  Nanomaterials (Basel)       Date:  2022-02-22       Impact factor: 5.076

3.  A Short Peptide of Autotransporter Ata Is a Promising Protective Antigen for Vaccination Against Acinetobacter baumannii.

Authors:  Peng Sun; Xin Li; Chao Pan; Zhicheng Liu; Jun Wu; Hengliang Wang; Li Zhu
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

Review 4.  STxB as an Antigen Delivery Tool for Mucosal Vaccination.

Authors:  Eric Tartour; Ludger Johannes
Journal:  Toxins (Basel)       Date:  2022-03-10       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.